Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
More than 40% of people treated with enfortumab vedotin experienced complete or partial remission.
Requires use of diagnostic tests for PD-L1 levels in tumor tissue from bladder cancer patients.
Decreased survival seen in some metastatic bladder cancer patients treated with pembrolizumab or atezolizumab monotherapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.